Biotest GmbH & Co. KGaA (HAM:BIO0)
33.20
0.00 (0.00%)
At close: Oct 14, 2026
Biotest GmbH & Co. KGaA Earnings Call Transcripts
Fiscal Year 2024
-
Sales grew 6% to €626 million in 2024, driven by new product launches and strong core sales, but EBIT fell due to lower technology transfer revenue. 2025 is expected to see a revenue decline and negative EBIT as R&D costs rise and price pressures persist. Delisting is planned, with Grifols offering €43/ordinary and €30/preference share.